Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Sophia Genetics SA

Healthcare US SOPH

4.96USD
0.18(3.77%)

Last update at 2026-06-04T20:11:00Z

Day Range

4.705.19
LowHigh

52 Week Range

2.137.37
LowHigh

Fundamentals

  • Previous Close 4.78
  • Market Cap314.45M
  • Volume139394
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-72.93600M
  • Revenue TTM62.37M
  • Revenue Per Share TTM0.96
  • Gross Profit TTM 31.25M
  • Diluted EPS TTM-1.12

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -79.62400M -87.58500M -73.50700M -41.22500M -33.62900M
Minority interest - - - - -
Net income -78.98100M -87.44900M -73.67500M -39.33900M -33.79100M
Selling general administrative 53.30M 55.82M 41.51M 18.96M 15.67M
Selling and marketing expenses 28.42M 28.27M 28.73M 17.43M 19.41M
Gross profit 36.68M 31.25M 25.22M 17.69M 17.83M
Reconciled depreciation 8.34M 5.57M 3.61M 2.39M 1.91M
Ebit -76.90900M -87.82300M -71.48900M -37.16500M -32.28700M
Ebitda -68.57300M -82.25200M -67.86000M -34.67900M -30.28800M
Depreciation and amortization 8.34M 5.57M 3.63M 2.49M 2.00M
Non operating income net other - - - - -
Operating income -76.90900M -87.82300M -71.48900M -37.16500M -32.28700M
Other operating expenses 139.28M 135.38M 111.94M 65.56M 57.65M
Interest expense 0.59M 0.64M 0.66M 0.84M 0.98M
Tax provision 0.49M -0.13600M 0.17M -1.88600M 0.16M
Interest income 4.55M 1.32M 0.02M 0.10M 0.09M
Net interest income 3.96M 0.69M -0.63800M -0.74400M -0.89000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.64300M -0.13600M 0.17M -1.88600M 0.16M
Total revenue 62.37M 47.56M 40.45M 28.40M 25.36M
Total operating expenses 113.58M 119.08M 96.71M 54.86M 50.12M
Cost of revenue 25.70M 16.31M 15.23M 10.71M 7.53M
Total other income expense net -2.71500M 0.24M -2.01800M -4.06000M -1.34200M
Discontinued operations - - - - -
Net income from continuing ops -78.98100M -87.44900M -73.67500M -39.33900M -33.79100M
Net income applicable to common shares - -87.44900M -73.67500M -39.33900M -33.79100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 206.16M 243.84M 320.17M 132.12M 51.66M
Intangible assets 18.19M 11.78M 7.38M 4.68M 2.40M
Earning assets - - - - -
Other current assets 3.11M 5.84M 0.62M 0.00900M 0.10M
Total liab 54.71M 43.71M 44.77M 31.61M 29.40M
Total stockholder equity 151.44M 200.13M 275.40M 100.51M 22.25M
Deferred long term liab - - - - 0.02M
Other current liab 20.94M 14.51M 20.38M 13.76M 12.24M
Common stock 4.05M 3.46M 3.33M 2.46M 1.95M
Capital stock 4.05M 3.46M 3.33M 2.46M 1.95M
Retained earnings -377.78400M -298.80300M -211.35400M -137.67900M -98.34000M
Other liab - 2.85M 4.92M 6.68M 4.87M
Good will 9.00M 8.19M 8.30M 8.60M 7.83M
Other assets - 6.22M 5.69M 3.60M 1.21M
Cash 123.25M 161.31M 192.96M 74.62M 18.07M
Cash and equivalents - - - - -
Total current liabilities 35.62M 26.81M 28.60M 21.59M 19.26M
Current deferred revenue 9.49M 3.43M 4.07M 2.64M 2.10M
Net debt -104.65000M -144.56200M -179.90300M -67.37600M -9.60500M
Short term debt 2.93M 2.69M 1.81M 3.91M 3.19M
Short long term debt - - - 2.87M 2.23M
Short long term debt total 18.60M 16.74M 13.06M 7.25M 8.46M
Other stockholder equity 471.20M 471.51M 470.89M 227.43M 119.23M
Property plant equipment - 21.40M 15.96M 5.54M 6.45M
Total current assets 148.05M 196.25M 282.86M 109.69M 33.76M
Long term investments - - - 0.78M 0.37M
Net tangible assets - 180.17M 259.73M 87.23M 12.02M
Short term investments 0.00000M 17.31M 72.36M 22.72M 0.37M
Net receivables 15.21M 6.65M 7.09M 7.85M 9.71M
Long term debt - - - 0.46M 1.61M
Inventory 6.48M 5.16M 5.73M 3.38M 3.61M
Accounts payable 2.26M 6.18M 2.34M 1.28M 1.73M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 53.98M 23.96M 12.54M 8.30M -0.58100M
Additional paid in capital - - - - -
Common stock total equity - - - 2.46M 1.95M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.10M 4.28M 3.70M 0.71M 0.84M
Deferred long term asset charges - - - - -
Non current assets total 58.11M 47.58M 37.32M 22.42M 17.90M
Capital lease obligations 18.60M 16.74M 13.06M 3.92M 4.63M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 8.32M 41.97M -50.26300M -21.11900M -21.11900M
Change to liabilities - -1.42800M 8.98M -0.18500M 5.60M
Total cashflows from investing activities - 41.97M -56.93400M -24.32300M -3.03300M
Net borrowings - -2.31600M -4.08500M -1.67000M -2.78300M
Total cash from financing activities -2.81700M -1.56800M 237.77M 107.05M -1.02300M
Change to operating activities - -0.97700M -2.33000M 2.35M -2.00900M
Net income -78.98100M -87.58500M -73.50700M -41.22500M -33.62900M
Change in cash -38.05400M -31.65700M 118.34M 56.56M -35.83800M
Begin period cash flow 161.31M 192.96M 74.62M 18.07M 53.91M
End period cash flow 123.25M 161.31M 192.96M 74.62M 18.07M
Total cash from operating activities -48.57500M -70.09300M -57.93900M -31.73000M -31.68000M
Issuance of capital stock 0.00000M -0.24400M 231.31M 107.64M 0.00000M
Depreciation 8.34M 5.57M 3.61M 2.39M 1.91M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.87400M -0.20000M -2.33600M 0.54M -0.86200M
Change to account receivables -6.50000M 1.33M 1.81M 1.12M -4.35200M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.23M -1.56800M 10.55M 16.91M -1.02300M
Change to netincome - 13.06M 6.01M 1.40M 1.82M
Capital expenditures 9.23M 10.38M 6.67M 3.20M 3.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.87M -1.27300M 6.12M 3.82M -1.62000M
Stock based compensation 15.24M 13.61M 8.51M 1.36M 0.72M
Other non cash items 7.08M 0.87M -1.07800M 2.69M 1.39M
Free cash flow -57.80100M -80.47400M -64.61000M -34.93400M -34.71300M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SOPH
Sophia Genetics SA		 0.18 3.77% 4.96 - - 5.20 2.15 3.54 -3.1702
VEEV
Veeva Systems Inc Class A		 -0.12 0.07% 178.60 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc		 - -% 8.55 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc		 0.08 1.70% 4.79 31.84 26.25 0.05 4.60 0.04 0.12
BTSG
BrightSpring Health Services, Inc. Common Stock		 -3.48 5.72% 57.40 100.22 40.65 0.69 4.92 0.92 25.80

Reports Covered

Stock Research & News

View All

Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Sophia Genetics SA

La Pièce 12, Rolle, Switzerland, 1180

Key Executives

Name Title Year Born
Dr. Jurgi Camblong M.B.A., Ph.D. Co-Founder, CEO & Director 1979
Mr. Ross Jordan Muken B.Sc. Sr. VP & CFO 1980
Mr. Abhimanyu Verma Sr. VP & CTO NA
Dr. Zhenyu Xu Ph.D. Sr. VP & Chief Scientific Officer 1982
Jennifer Pottage Head of Investor Relations NA
Mr. Daan van Well L.L.M., M.B.A. Sr. VP, Chief Legal Officer & Gen. Counsel 1974
Ms. Manuela Da Silva Valente B.A. Sr. VP & Chief People Officer 1970
Dr. Thierry Colin Sr. VP of Radiomics Bus. Area NA
Dr. Philippe Menu M.B.A., M.D., Ph.D. Sr. VP & Chief Medical Officer 1981
Ms. Lara Hashimoto Sr. VP & Chief Bus. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions